Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

292

Enrollment

INDUSTRY

Sponsor class

Stopped GSK decision

Conditions

Non-alcoholic Steatohepatitis
Chronic Liver Disease
HCV
NASH - Nonalcoholic Steatohepatitis
HIV Infection
Thrombocytopenia
Hepatitis C Virus
HBV
Human Immunodeficiency Virus
Liver Diseases
Hepatitis B Virus

Interventions

DRUG: Eltrombopag
DRUG: Placebo

Sponsor

GlaxoSmithKline